Breakthrough in depression treatment: neurosteroids, psilocybin and Caplyta
FDA approved zuranolone, psilocybin passed phase III, and Caplyta doubles the chance of remission. Learn how moving away from the serotonin theory and new NMDA antagonists are changing psychiatry in 2026.
